Drug may slow tumor growth in men with advanced prostate cancer.
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013467:Sulindac / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D013467:Sulindac; D015106:3',5'-Cyclic-GMP Phosphodiesterases; C025463:sulindac sulfone